Market Closed -
OTC Markets
01:29:29 30/05/2024 am IST
5-day change
1st Jan Change
0.0017
USD
0.00%
+183.33%
-43.33%
Bloomios, Inc. announced that it has received $0.25 million in funding
On December 3, 2021, Bloomios, Inc. closed the transaction.
Involuntary Petition Filed Against Bloomios, Inc.
15/04
CI
Bloomios, Inc. Ceases Manufacturing At the Facility and Terminated All Employees
08/03
CI
Bloomios, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
21/11
CI
Bloomios, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
21/23/21
CI
Bloomios, Inc. Provides Revenue Guidance for the Second Quarter of 2023
02/23/02
CI
Bloomios, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
19/23/19
CI
Bloomios, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
18/23/18
CI
Bloomios, Inc. Auditor Raises 'Going Concern' Doubt
17/23/17
CI
Bloomios, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22/22/22
CI
Bloomios, Inc. announced that it has received $0.852941 million in funding
15/22/15
CI
Bloomios, Inc. Closes on an Offering of the Debentures
01/22/01
CI
Bloomios, Inc. acquired Infusionz, LLC from Upexi, Inc. for $23.5 million.
27/22/27
CI
Bloomios, Inc. announced that it has received $2.083958 million in funding
26/22/26
CI
Bloomios, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
23/22/23
CI
Bloomios, Inc. to Develop and Produce New Range of Private-Label Products Utilizing, Ashwagandha, Melatonin, Kratom, Lion's Mane, Valerian Root, Reishi Mushroom and Other Natural Ingredients
05/22/05
CI
Bloomios Expands Production Capacity by 300%, Setting Stage for Strong Growth in 2022
18/22/18
CI
Bloomios, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
13/22/13
CI
Earnings Flash (BLMS) BLOOMIOS Posts Q4 Revenue $1.7M
19/22/19
MT
Bloomios, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
16/22/16
CI
Bloomios, Inc. Auditor Raises 'Going Concern' Doubt
15/22/15
CI
Bloomios, Inc. Announces Selection as the Exclusive Cannabidiol Product Manufacturer for DRYWORLD
01/22/01
CI
Bloomios, Inc. announced that it has received $0.25 million in funding
03/21/03
CI
Bloomios, Inc. announced that it expects to receive $0.25 million in funding
30/21/30
CI
Bloomios, Inc. Provides Earnings Guidance for the Year 2021
17/21/17
CI
Bloomios, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
15/21/15
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Bloomios, Inc. manufactures, markets, and distributes hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States, through its wholly owned subsidiary, Bloomios Private Label (BPL). BPL is engaged in the manufacturing, processing, sourcing and distribution of hemp-derived, nootropic and nutraceutical products to wholesalers and retailers. The Company manufactures hemp infused products ranging from human edibles, pet edibles, liquid consumables such as tinctures and shots, topicals, and smokable hemp. It provides support at each step from custom formulation, order fulfillment, and brand development. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages and pet treats. It offers its private-label and white-label customers a collections of customizable hemp products that includes over 80 products across seven categories in addition to custom formulation and manufacturing services.
More about the company
1st Jan change
Capi.
-43.33% 115K -.--% 339M +18.11% 232M +3.09% 213M +38.37% 180M +145.74% 140M -28.57% 121M +29.80% 117M -46.53% 110M +7.69% 93.5M
Medical Farming
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
BLOOMIOS, INC. 
